1 |
Vauthier, C., Couvreur, P., 2000. Development of nanoparticles made of polysaccharides as novel drug carrier systems. In D.L. Wise (ed.), Handbook of Pharmaceutical Controlled Release Technology, Marcel Dekker, New York, 413-429.
|
2 |
Violanto, M.R., 1989. Method for making uniformly sized particles from water-insoluble organic compounds. US Patent 4,826,689.
|
3 |
Volcheck, G.W., Van Dellen, R.G., 1998. Anaphylaxis to intravenous cyclosporine and tolerance to oral cyclosporine: case report and review. Ann. Allergy, Asthma, & Immun. 80, 159-163.
DOI
|
4 |
Vorum, H., 1999. Reversible ligand binding to human serum albumin. Theoretical and clinical aspects. Dan Med Bull. 46, 379-399.
|
5 |
Weber, C., Kreuter, J., Langer, K., 2000. Desolvation process and surface characteristics of HSA-nanoparticles. Int. J. Pharm. 196, 197-200.
DOI
|
6 |
Weiss, R.B., Donehower, R.C., Wiernik, P.H., Ohnuma, T., Gralla, R.J., Trump, D.L., Baker Jr., J.R., Van Echo, D.A., Von Hoff, D.D., Leyland-Jones, B., 1990. Hypersensitivity reactions from Taxol. J. Clin. Oncol. 8, 1263-1268.
DOI
|
7 |
Yang, L., Cui, F., Cun, D., Tao, A., Shi, K., Lin, W., 2007. Preparation, characterization and biodistribution of the lactone form of 10-hydroxycamptothecin (HCPT)-loaded bovine serum albumin (BSA) nanoparticles. Int. J. Phram. 340, 163-172.
DOI
|
8 |
Toub, N., Malvy, C., Fattal, E., Couvreur, P., 2006. Innovative nanotechnologies for the delivery of oligonucleotides and siRNA. Biomed. Pharmacother. 60, 607-620.
DOI
|
9 |
Van Zuylen, L., Verweij, J., Sparreboom, A., 2001. Role of formulation vehicles in taxane pharmacology. Invest. New Drugs 19, 125-141.
DOI
|
10 |
Pavanetto, F., Genta, I., Giunchedi, P., Conti, B., Conte, U., 1994. Spray-dried albumin microspheres for the intra-articular delivery of dexamethasone. J. Microencapsulation 11, 445-454.
DOI
|
11 |
Peters, T., 1985. Serum albumin, Adv. Protein Chem. 37, 161-245.
DOI
|
12 |
Porter, P.L., Sage, E.H., Lane, T.F., Funk, S.E., Gown, A.M., 1995. Distribution of SPARC in normal and neoplastic human tissue. J. Histochem. Cytochem. 43, 791-800.
DOI
ScienceOn
|
13 |
Purcell, M., Neault, J.F., Tajmir-Riahi, H.A., 2000. Interaction of Taxol with human serum albumin. Biochim. Biophys. Acta. 1478, 61-68.
DOI
|
14 |
Reis, C.P., Neufeld, R.J., Ribeiro, A.J., Veiga, F., 2006. Nanoencapsulation I. Methods for preparation of drug-loaded polymeric nanoparticles. Nanomedicine 2, 8-21.
DOI
ScienceOn
|
15 |
Rustgi, V.K., 2009. Albinterferon alfa-2b, a novel fusion protein of human albumin and human interferon alfa-2b, for chronic hepatitis C. Curr. Med. Res. Opin. 25, 991-1002.
DOI
|
16 |
Sah, H., 1999. Stabilization of proteins against methylene chloride/water interface-induced denaturation and aggregation. J. Control. Release 58, 143-151.
DOI
|
17 |
Sheu, M.T., Moustafa, M.A., Sokoloski, T.D., 1986. Entrapment of bioactive compounds within native albumin beads: II. Effects of rate and extent of crosslinking on microbead properties. J. Parent. Sci. Technol. 40, 253-258.
|
18 |
Meeh, L., Cacheris, W.P., 1994. Microfluidization of calcium/oxyanion-containing particles. US Patent 5,342,609.
|
19 |
Sheu, M.T., Sokoloski, T.D., 1986. Entrapment of bioactive compounds within native albumin beads: III. Evaluation of parameters affecting drug release. J. Parent. Sci. Technol. 40, 259-265.
|
20 |
Sheu, M.T., Sokoloski, T.D., 1991. Entrapment of bioactive compounds within native albumin beads: IV. Characterization of drug release from polydisperse systems. Int. J. Pharm. 71, 7-18.
DOI
|
21 |
Merisko-Liversidge, E., Sarpotdar, P., Bruno, J., Hajj, S., Wei, L., Peltier, N., Rake, J., Shaw, J.M., Pugh, S., Polin, L., Jones, J., Corbett, T., Cooper, E., Liversidge, G.G., 1996. Formulation and antitumor activity evaluation of nanocrystalline suspensions of poorly soluble anticancer drugs. Pharm. Res. 13, 272-278.
DOI
|
22 |
Michaelis, K., Hoffmann, M.M., Dreis, S., Herbert, E., Alyautdin, R.N., Michaelis, M., Kreuter, J., Langer, K., 2006. Covalent linkage of apolipoprotein E to albumin nanoparticles strongly enhances drug transport into the brain. J. Pharm. Exp. Ther. 317, 1246-1253.
DOI
|
23 |
Minshall, R.D., Tiruppathi, C., Vogel, S.M., Malik, A.B., 2002. Vesicle formation and trafficking in endothelial cells and regulation of endothelial barrier function. Histochem. Cell Biol. 117, 105-112.
DOI
|
24 |
Morlock, M., Knoll, H., Winter, G., Kissel, T., 1997. Microencapsulation of rh-erythropoietin, using biodegradable poly (D,L-lactide-co-glycolide): protein stability and the effects of stabilizing excipients. Eur. J. Pharm. Biopharm. 43, 29-36.
DOI
|
25 |
Mosqueira, V.C., Legrand, P., Morgat, J.L., Vert, M., Mysiakine, E., Gref, R., Devissaguet, J.P., Barratt, G., 2001. Biodistribution of long-circulating PEG-grafted nanocapsules in mice: effects of PEG chain length and density. Pharm. Res. 18, 1411-1419.
DOI
|
26 |
Kreuter, J., 2004. Nanoparticles as drug delivery systems. In Nalwa, H.S. (Ed.), Encyclopedia of Nanoscience and Nanotechnology, vol. 7. American Scientific Publishers, Stevenson Ranch, USA, 161-180.
|
27 |
Muller, G.M., Leuenberger, H., Kissel, T., 1996. Albumin nanospheres as carriers for passive drug targeting: an optimized manufacturing technique. Pharm. Res. 13, 32-37.
DOI
|
28 |
Ohkawa, K., Hatano, T., Yamada, K., Joh, K., Takada, K., Tsukada, Y., Matsuda, M., 1993. Bovine serum albumin-doxorubicin conjugate overcomes multidrug resistance in a rat hepatoma. Cancer Res. 53, 4238-4242.
|
29 |
Paal, K., Muller, J., Hegedus, L., 2001. High affinity binding of paclitaxel to human serum albumin. Eur. J. Biochem. 268, 2187-2191.
DOI
|
30 |
Kumar, G.N., Walle, U.K., Bhalla, K.N., Walle, T., 1993. Binding of taxol to human plasma, albumin, and alpha1-acid glycoprotein. Research Communications in Chemical Pathology and Pharmacology 80, 337-344.
|
31 |
Lambert, G., Fattal, E., Pinto-Alphandary, H., Gulik, A., Couvreur, P., 2000. Polyisobutylcyanoacrylate nanocapsules containing an aqueous core as a novel colloidal carrier for the delivery of oligonucleotides. Pharm. Res. 17, 707-714.
DOI
|
32 |
Langer, K., Balthasar, S., Vogel, V., Dinauer, N., von Briesen, H., Schubert, D., 2003. Optimization of the preparation process for human serum albumin (HSA) nanoparticles. Int. J. Pharm. 257, 169-180.
DOI
|
33 |
Lee, T.K., Sokoloski, T.D., Royer, G.P., 1981. Serum albumin beads: an injectable, biodegradable system for the sustained release of drugs. Science 213, 233-235.
DOI
|
34 |
Lidgate, D.M., Tranner, T., Shultz, R.M., Maskiewicz, R., 1990. Sterile filtration of a parenteral emulsion. Pharm. Res. 9, 860-863.
DOI
|
35 |
Koosha, F., Muller, R.H., 1988. Nanoparticle production by microfluidization. Archiv Der Pharmazie 321, 680.
|
36 |
John, T.A., Vogel, S.M., Tiruppathi, C., Malik, A.B., Minshall, R.D., 2003. Quantitative analysis of albumin uptake and transport in the rat microvessel endothelialmonolayer. Am. J. Physiol., Lung Cell. Mol. Physiol. 284, 187-196.
DOI
|
37 |
Jung, T., Kamm, W., Breitenbach, A., Kaiserling, E., Xiao, J.X., Kissel, T., 2000. Biodegradable nanoparticles for oral delivery of peptides: is there a role for polymers to affect mucosal uptake? Eur. J. Pharm. Biopharm. 50, 147-160.
DOI
|
38 |
Kloover, J.S., den Bakker, M.A., Gelderblom, H., van Meerbeeck, J.P., 2004. Fatal outcome of a hypersensitivity reaction to paclitaxel: a critical review of premedication regimens. Br. J. Cancer 90, 304-305.
DOI
|
39 |
Kragh-Hansen, U., 1981. Molecular aspects of ligand binding to serum albumin. Pharmacological Reviews 33, 17-53.
|
40 |
Garrido, M.J., Jimenez, R.M., Rodriguez-Sasiain, J.M., Aguirre, C., Aguilera, L., Calvo, R., 1994. Caracterizacion de la fijacion de propofol a las proteinas plasmaticas y posibles interacciones. Rev. Esp. Anestestiol. Reanim. 41, 308-312.
|
41 |
Gelderblom, H., Verweij, J., Nooter, K., Sparreboom A., 2001. Cremophor EL: The drawbacks and advantages of vehicle selection for drug formulation. Eur. J. Cancer 37, 1590-1598.
DOI
|
42 |
Gianni, L., Kearns, C.M., Giani, A., Capri, G., Vigano, L., Lacatelli, A., Bonadonna, G., Egorin, M.J., 1995. Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans. J. Clin. Oncol. 13, 180-190.
DOI
|
43 |
Gligorov, J., Lotz, J.P., 2004. Preclinical pharmacology of the taxanes: implications of the differences. Oncologist 9, 3-8.
|
44 |
Dye, D., Watkins, J.,1980. Suspected anaphylactic reaction to Cremophor EL. Br. Med. J. 280, 1353.
|
45 |
Doegito, E., Fessi, H., Appel, M., Puisieux, F., Bolard, J., Devissaguet, J.P., 1994. New techniques for preparing submicronic emulsions-application to Amphotericine-B. STP Pharma Sciences 4, 155-162.
|
46 |
Dreis, S., Rothweiler, F., Michaelis, M., Cinatl Jr., J., Kreuter, J., Langer, K., 2007. Preparation, characterisation and maintenance of drug efficacy of doxorubicin-loaded human serum albumin (HSA) nanoparticles. Int. J. Pharm. 341, 207-214.
DOI
|
47 |
Duncan, R., 2003. The dawning era of polymer therapeutics. Nat. Rev. Drug Discov. 2, 347-360.
DOI
|
48 |
Eatock, M., Church, N., Harris, R., Angerson, W., McArdle, C., French, R., Twelves, C., 1999. Activity of doxorubicin covalently bound to a novel human serum albumin microcapsule. Invest. New Drugs 17, 111-120.
DOI
|
49 |
Faithfull, N.S., Cain, S.M., 1988. Cardiorespiratory consequences of flurocarbon reactions in dogs. Bio. Art. Organs 16, 463-472.
|
50 |
Fehske, K.J., Muller, W.E., Wollert, U., 1981. The location of drug binding sites in human serum albumin. Biochem Pharmacol. 30, 687-692.
DOI
|
51 |
Couvreur, P., Vauhtier, C., 2006. Nanotechnology: intelligent design to treat complex disease. Pharm. Res. 23, 1417-1450.
DOI
|
52 |
Curry, S., Mandelkow, H., Brick, P., Franks, N., 1998. Crystal structure of human serum albumin complexed with fatty acid reveals an asymmetric distribution of binding sites. Nat. Struct. Biol. 5, 827-835.
DOI
|
53 |
Carter, D.C., Ho, J.X., 1994. Structure of serum albumin. Adv. Protein Chem. 45, 153-203.
DOI
|
54 |
Barraud, L., Merle, P., Soma, E., Lefrancois, L., Guerret, S., Chevallier, M., Dubernet, C., Couvreur, P., Trepo, C.,Vitvitski, L., 2005. Increase of doxorubicin sensitivity by doxorubicin-loading into nanoparticles for hepatocellular carcinoma cells in vitro and in vivo. J. Hepatol. 42, 736-743.
DOI
|
55 |
Bodmeier, R., Chen, H., 1990. Indomethacin polymeric nanosuspensions prepared by microfluidization. J. Control. Release 12, 223-233.
DOI
|
56 |
Busch-vishniac, I., Buckman, A.B., Pavuluri, J.K., Wang, W., Qian, D., Mancevski, V., 1996. Noncontact position measurement system using optical sensors. US Patent 5,552,883.
|
57 |
Chanasattru, W., Jones, O.G., Decker, E.A., McClements, D.J., 2009. Impact of cosolvents on formation and properties of biopolymer nanoparticles formed by heat treatment of
-lactoglobulin-pectin complexes. Food Hydrocolloids 23, 2450-2457
DOI
|
58 |
Chen, G.Q., Lin, W., Coombes, A.G.A., Davis, S.S., Illum, L., 1994. Preparation of human serum albumin microspheres by a novel acetone-heat denaturation method. J. Microencapsulation 11, 395-407.
DOI
|
59 |
Coombes, A.G.A., Breeze, V., Lin, W., Gray, T., Parker, K.G., Parker, T., 2001. Lactic acid-stabilized albumin for microsphere formation and biomedical coating. Biomaterials 22, 1-8.
DOI
|
60 |
Coombes, A.G.A., Lin, W., O'Hagen, D.T., Davis, S.S., 2003. Preparation of protein microspheres, films and coating. US Patent 6,592,844.
|
61 |
Ten Tije, A.J., Verweij, J., Loos, W.J., Sparreboom, A., 2003. Pharmacological effects of formulation vehicles: implications for cancer chemotherapy. Clin. Pharmacokinet. 42, 665-685.
DOI
|
62 |
Slack, J.D., Kanke, M., Simmons, G.H., DeLuca, P.P., 1981. Acute hemadynamic effects and blood pool kinetics of polystyrene microspheres following intravenous administration. J. Pharm. Sci. 70, 660-664.
DOI
|
63 |
Sugio, S., Kashima, A., Mochizuki, S., Noda, M., Kobayashi, K., 1999. Crystal structure of human serum albumin at 2.5 resolution. Protein Eng. 12, 439-446.
|
64 |
Talsma, H., Ozer, A.Y., VanBloois, L., Crommelin, D.J., 1989. The size reduction of liposomes with a high pressure homogenizer (microfluidizer): Characterization of prepared dispersions and comparison with conventional methods. Drug Dev. Ind. Pharm. 15, 197-207.
DOI
|
65 |
Thibaudeau, K., Léger, R., Huang, X., Robitaille, M., Quraishi, O., Soucy, C., Bousquet-Gagnon, N., van Wyk, P., Paradis, V., Castaigne, J.P., Bridon, D., 2005. Synthesis and evaluation of insulin-human serum albumin conjugates. Bioconjugate Chemistry 16, 1000-1008.
DOI
|
66 |
Tomkin, G.H., 2009. Albiglutide, an albumin-based fusion of glucagon-like peptide 1 for the potential treatment of type 2 diabetes. Curr. Opin. Mol. Ther. 11, 579-588.
|
67 |
Torchilin, V.P., Trubetskoy, V.S., 1995. Which polymers can make nanoparticulate drug carriers long-circulating? Adv. Drug Deliv. Rev. 16, 141-155.
DOI
|
68 |
Lorenz, W., Reimann, H.J., Schmal, A., Dormann, P., Schwarz, B., Neugebauer, E., Doenicke, A., 1977. Histamine release in dogs by Cremophore EL and its derivatives: Oxethylated oleic acid is the most effective constituent. Agents and Actions 7, 63-67.
DOI
|
69 |
Liversidge, G.G., Cundy, K.C., Bishop, J.F., Czekai, D.A., 1992. Surface modified drug nanoparticles. US Patent 5,145,684.
|
70 |
Liversidge, G.G., Liversidge, E., Sarpotdar, P.P., 1995. Surface modified anticancer nanoparticles. US Patent 5,399,363.
|
71 |
Maeda, H., Wu, J., Sawa, T., Matsumura, Y., Hori, K., 2000. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J. Control. Release 65, 271-284.
DOI
ScienceOn
|
72 |
Howard, K.A., Kjems, J., 2007. Polycation-based nanoparticle delivery for improved RNA interference therapeutics. Expert. Opin. Biol. Ther. 7, 1811–1822.
|
73 |
Ibrahim, N.K., Desai, N., Legha, S., Soon-Shiong, P., Theriault, R.L., Rivera, E., Esmaeli, B., Ring, S.E., Bedikian, A., Hortobagyi, G.N., Ellerhorst, J.A., 2002. Phase I and pharmacokinetic study of ABI-007, a cremophor-free, proteinstabilized, nanoparticle formulation of paclitaxel. Clin. Cancer Res. 8, 1038-1044.
|
74 |
Ikuta, S., Chuang, V.T.G., Ishima, Y., Nakajou, K., Furukawa, M., Watanabe, H., Maruyama, T., Otagiri, M., 2010. Albumin fusion of thioredoxinæThe production and evaluation of its biological activity for potential therapeutic applications. J. Control. Release 147, 17-23.
DOI
|
75 |
Jette, L., Léger, R., Thibaudeau, K., Benquet, C., Robitaille, M., Pellerin, I., Paradis, V., van Wyk, P., Pham, K., Bridon D.P., 2005. Human growth hormone-release factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: Identification of CJC-1295 as a long-lasting GRF analog. Endocrinology 146, 3052-3058.
DOI
|
76 |
Hawkins, M.J., Soon-Shiong, P., Desai, N., 2008. Protein nanoparticles as drug carriers in clinical medicine. Advanced Drug Delivery Reviews 60, 876-885.
DOI
|
77 |
Gradishar, W.J., Tjulandin, S., Davidson, N., Shaw, H., Desai, N., Bhar, P., Hawkins, M., O’Shaughnessy, J., 2005. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J. Clin. Oncol. 23, 7794-7803.
DOI
|
78 |
Gregoriadis, G., Da Silva, H., Florence, A.T., 1990. A procedure for the efficient entrapment of drugs in dehydration-rehydration liposomes (DRVs). Int. J. Pharm. 65, 235-242.
DOI
|
79 |
Grunewalder, J.F., Voelker, M.A., 1993. Water-borne treatment compositions for porous substrates. US Patent 5,228,905.
|
80 |
He, X.M., Carter, D.C., 1992. Atomic structure and chemistry of human serum albumin. Nature 358, 209-215.
DOI
|
81 |
Holmes, D.L., Thibaudeau, K., L'Archevêque, B., Milner, P.G., Ezrin, A.M., Bridon, D.P., 2000. Site specific 1:1 opoid:albumin conjugate with in vitro activity and long in vivo duration. Bioconjugate Chemistry 11, 439-444.
DOI
|
82 |
Desai, N.P., Soon-Shiong, P., Sandford, P.A., Grinstaff, M.W., Suslick, K.S., 1995. Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor. US Patent 5,439,686.
|
83 |
Desai, N.P., Tao, C., Yang, A., Louie, L., Zheng, T., Yao, Z., Soon-Shiong, P., Magdassi, S., 1999. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof. US Patent 5,916,596.
|
84 |
Desai, N.P., Yang, A., De, T., Ci, S.X., Soon-shiong, P., Trieu, V., Yao, O., Grim, B.B., 2005. Compositions and methods of delivery of pharmacological agents. US Patent app. Pub. No. 2005/0004002A1.
|
85 |
Desai, N., Trieu, V., Yao, Z., Louie, L., Ci, S., Yang, A., Tao, C., De, T., Beals, B., Dykes, D., Noker, P., Yao, R., Labao, E., Hawkins, M., Soon-Shiong, P., 2006. Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clin. Cancer Res. 12, 1317-1324.
DOI
ScienceOn
|
86 |
Damascelli, B., Cantu, G., Mattavelli, F., Tamplenizza, P., Bidoli, P., Leo, E., Dosio, F., Cerrotta, A.M., Di Tolla, G., Frigerio, L.F., Garbagnati, F., Lanocita, R., Marchiano, A., Patelli, G., Spreafico, C., Ticha, V., Vespro, V., Zunino, F., 2001. Intraarterial chemotherapy with polyoxyethylated castor oil free paclitaxel, incorporated in albumin nanoparticles (ABI-007): phase II study of patients with squamous cell carcinoma of the head and neck and anal canal: preliminary evidence of clinical activity. Cancer 92, 2592-2602.
DOI
|
87 |
De Garavilla, L., Liversidge, E.M., Liversidge, G.G., 1998. Reduction of intravenously administered nanoparticulate-formulation-induced adverse physiological reactions. US Patent 5,834,025.
|
88 |
Desai, N., Trieu, V., Vao, R., Frankel, T., Soon-Shiong, P., 2004. SPARC expression in breast tumors may correlate to increased tumor distribution of nanoparticle albumin-bound paclitaxel (ABI-007) vs Taxol. Presented at the 27th Annual San Antonio Breast Cancer Symposium, San Antonio, Texas.
|
89 |
Desai, N.P., Soon-Shiong, P., De, T.K., 2010. Methods and compositions for treating proliferative diseases. US Patent 7,780,984.
|
90 |
Avgoustakis, K., 2004. Pegylated poly(lactide) and poly(lactidecoglycolide) nanoparticles: preparation, properties and possible applications in drug delivery. Curr. Drug Deliv. 1, 321-333.
DOI
|
91 |
Bagchi, P., Stewart, R.C., Mclntire, G.L., Minter, J.R., 1997. Microprecipitation of micro-nanoparticulate pharmaceutical agents. US Patent 5,662,883.
|
92 |
Altmayer, P., Büch, U., Büch, H.P., 1995. Arzneimittelforschung 45, 1053-1056.
|